Glenmark launches Ryaltris-AZ at affordable price
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
Subscribe To Our Newsletter & Stay Updated